A model assessing sequential olfactory testing and dopamine transporter (DAT) imaging for screening pre-motor Parkinson's Disease (PD) was adapted to a European setting with German cost and health utility data. METHODS: PD Associated Risk Study (PARS) data were used to parameterize screening efficacy. Screening strategies in persons 1) in a general population, 2) with a relative with PD, 3) with LRRK2ϩ genotype, and 4) with REM sleep disorder were evaluated. PD prevalence per 100 at screening was 0.5, 2, 10 and 20 for these groups. Olfactory test and DAT costs were €11 and €1500, respectively. We assumed disease modifying (DM) therapy was available that slowed disease progression by 20% at a cost of €30,000. Economic value was measured in net monetary benefits (NMB), valuing a qualityadjusted life-year at €50,000. RESULTS: Screening sensitivity and specificity were 64% and 99%, respectively. 13.4% had positive results on the olfactory test and also took the DAT. NMB for the four groups was €-169, €269, €2,603, and €5,521, indicating that screening has positive economic value in persons with a close relative with PD, persons with LRRK2ϩ genotype, and persons with REM sleep disorder. Screening value was positively correlated with rate of progression from preclinical to clinical PD, efficacy of DM therapy, and QALY monetization. Screening value was negatively correlated with costs of false positives, screening cost, age at onset, Hoehn and Yahr stage at which the unscreened diagnosis is made, and cost of DM therapy. CONCLUSIONS: Screening for early PD may be a cost-effective strategy for certain risk groups.
OBJECTIVES: New diagnostic approaches, including molecular profiling, have improved the ability to establish accurate diagnoses of hematologic cancers, but have also increased the complexity of test ordering, information integration and interpretation. This study examined the role of specialty and other laboratory providers, the types of diagnostic tests provided for patients with suspected hematologic cancers, and subsequent health care costs. METHODS: Patients with bone marrow biopsies and suspected hematologic cancer/condition (2005) (2006) (2007) (2008) (2009) (2010) (2011) were identified from claims data from a large US health plan. Included patients had Ն6 pre-& Ն3-months post-biopsy health plan coverage. Lab tests in the 30 days post-biopsy were identified. Patient cohorts were based upon laboratories performing marrow morphologic assessment/directing testing sequence: Genoptix (GX, a specialty hematology-testing laboratory); large commercial laboratories (LL), other laboratories (OL); academic labs were excluded. Diagnostic/treatment medical costs (per-patient-per-month) during the 30-days & 1 year post-biopsy were examined (ANOVA). RESULTS: Of 30,393 patients with suspected hematologic malignancy/condition, 94.25% had marrow morphology reviewed. OL patients were slightly younger (58.19 OL vs. , 59.88 GX, 59 .39 LL, PϽ0.001). More flow cytometry was done at GX (96.68%) vs 87.68% in LL and 69.78% in OL. Cytogenetics/FISH analysis rates were: 95.96% GX, 80.78% LL, 51.68% OL. Use of molecular diagnostics was less common (26.03% in GX, 14.27% in LL and 9.31% in OL). 1-year PPPM costs were $4487 GX, $4325 LL, and $5407 OL (PϽ0.001)); costs PPPM excluding the testing period were $2132 GX, $2686 LL, and $3341 OL (PϽ0.001). CONCLUSIONS: Frequency of diagnostic tests in the 30-days post-biopsy varied, with complex tests conducted more frequently in the hematology specialty laboratory. However, disease-related costs with the specialty laboratory were lower than costs for some laboratories with lower use of these tests. Further exploration of the impact of alternative diagnostic testing approaches on costs and clinical outcomes is warranted.
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PRE-SCREENING TOOLS: A NEGLECTED APPROACH TO DIAGNOSE AND CUT COST ASSOCIATED WITH OSTEOPOROSIS
Khan Y, Sarriff A, Hayat khan A, Hassali MAA University Sains Malaysia, penang, penang, Malaysia OBJECTIVES: Due to high cost and limited availability of dual-energy x-ray absorptiometry (DXA), 77 percent of high risk population remains undiagnosed and therefore untreated for osteoporosis. To cope up with current scenario, pre-screening tools have become apparent as pragmatic tool for extensive screening of osteoporosis. Use of such tools would help health care professionals to make better use of bone densitometry and to cut billions of dollars cost associated with DXA. This study attempts to evaluate possible reasons that pose hindrance in implementation of such tools despite of reliability and cost effective nature of such tools. METHODS: Using convenience sampling method, a pre-validated questionnaire was used to conduct a cross-sectional survey among health care professionals in Malaysia. 5 endocrinologists, 10 orthopedic specialists, 25 medical officers, 30 hospital pharmacists participated from Hospital Pulau Penang while 33 community pharmacists and 27 general practitioners from Penang participated in survey(total 130). RESULTS: There was no statistically significant difference regarding knowledge of pre-screening tools among health care professionals belonging to different specialties. Although, 77% of participants have heard about pre-screening tools but only 53 % were able to identify the purpose of such tools. Out of list of 8 prescreening tools, majority 36 % identified SCORE followed by MOST (22 %) as prescreening tools while other tools were not identified. Only 5 % of participants have used such tools while 94 % showed willingness to use such tools and to encourage patients to undergo screening by such tools. Majority 61 % preferred leaflets/ brochures to gain information regarding availability and utility of such tools while least 13 % preferred continuous education programs. CONCLUSIONS: Proper awareness regarding availability and utility of such tools would not only help to improve patient's quality of life also it would help to reduce global economic burden associated with osteoporosis. OBJECTIVES: Few data exists on high cardiovascular risk (HCVR) prevalence within a primary prevention population. The goal of the study was to assess HCVR distribution, according to the European SCORE risk assessment scale, in France in highrisk primary care patients not treated with lipid-lowering drug. METHODS: This observational study was conducted over a week on a representative sample of French general practitioners (GP). All consulting primary care men/women Ն50/60 y, with at least one other CVR factor (smoking, high blood pressure (HBP), type 2 diabetes, HDL-cϽ0.40 g/L), not treated for dyslipidemia were included in the study. GP filled-in an on line questionnaire that enabled SCORE calculation. RESULTS: GPs (nϭ1147) included 9049 patients (mean age: 68 y; male: 57%; LDLcϾ1.3 g/L: 57%; smoking: 21%; HBP: 44%; type 2 diabetes: 21% HDL-cϽ0.4 g/L: 16%). According to SCORE, HCVR prevalence reached 50% in total population (male: 49%, female: 51%). 50% of HCVR men/women were older than Ͼ72.4/78.8 y. HCVR patients were older by 7.7/6.8 y for male/female (p Ͻ0.01) than non-HCVR patients. Other significantly more frequent characteristics in high CVR population are: HDLՆ0.6 g/L (38%), untreated or uncontrolled HBP (53%) and left ventricular hypertrophy (8%). Obesity is less frequent (15%) in high CVR population. Highest HCVR prevalence was observed in the Mediterranean population (54%), and lowest (47%) in the Northeast population (p Ͻ0.01). Adjustment by age and gender reduces regional disparities (52% vs 48%). CONCLUSIONS: Half consulting primary care patients aged Ն50/60 y for men/ women with at least 1 risk factor on top of age and no lipid-lowering treatment are at HCVR according to SCORE risk equation. Assessing cardiovascular risk with risk equations appears particularly useful in this group of patients. Besides age, which has the strongest impact on risk estimation, other RF may be screened to improve HCVR management.
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PMD5 CLINICAL AND COST-EFFECTIVENESS OF THIRD-GENERATION, IMPLANTABLE LEFT VENTRICULAR ASSIST DEVICES FOR PEOPLE WITH END-STAGE HEART FAILURE: A SYSTEMATIC REVIEW
Jaworska E, Wlodarczyk A, Budasz-Swiderska M Agency for Health Technology Assessment In Poland (AHTAPol), Warsaw, Poland OBJECTIVES: To systematically review the current clinical and cost-effectiveness literature of third-generation, implantable left ventricular assist devices (LVADs) for people with end-stage heart failure (ESHF). METHODS: Three implantable, third-generation LVADs were identified as available in the EU. A systematic literature review was conducted of published and unpublished cost-effectiveness and clinical data (comparative studies) in the ESHF population, since their inception till April 2012, using a number of medical databases. RESULTS: One relevant economic evaluation and four comparative clinical studies (1 vs. virtual control arm & 3 vs. older-generation LVADs) met the inclusion criteria. Therapy success defined as survival LVAD or explant to receive a heart transplant or for recovery, occurred in approx. 92.0% of patients with third-generation LVADs and 90.1% of control patients (second-generation LVAD) in a 6-months period. The 1-year survival of patients who were implanted with third-generation LVADs ranged from 82% to 91%. The most frequently reported adverse events were arrhythmias, bleeding, infection, respiratory and renal failure, right heart failure, and stroke. One included study evaluates the cost-effectiveness of the implantable, third-generation LVADs as destination therapy for patients with ESHF as compared to patients on medical management in the UK. Results showed that at 5ys LVADs had an additional cost of about £20,500 per patient and QALY gain of 1.05, giving an incremental cost per QALY of £19 500, which is below the commonly adopted threshold of £25,000 per QALY. However, this finding seems unreliable due to controversial assumptions. CONCLUSIONS: Despite the poor methodological quality of included studies, thirdgeneration of implantable LVADs seems beneficial due to improving survival, therapy success and functional status. Adverse events serious concern. No prospective controlled data are available as bridge to recovery, nor destination therapy. There is an urgent need for additional, reliable cost-effectiveness studies evaluating third-generation pumps versus previous generations of LVADs.
